Valuation: Insmed Incorporated

Market Cap 26.38B 23.16B 21.77B 19.9B 37.19B 2,527B 37.47B 261B 101B 1,289B 99.08B 96.91B 4,178B P/E 2026 *
-73.8x
P/E 2027 * 163x
Enterprise Value 25.75B 22.6B 21.25B 19.43B 36.3B 2,467B 36.57B 255B 98.94B 1,258B 96.71B 94.59B 4,078B EV / Sales 2026 *
14.3x
EV / Sales 2027 * 8.79x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day-2.18%
1 week-3.16%
Current month-2.55%
1 month-4.25%
3 months+16.21%
6 months-17.55%
Current year-31.79%
1 week 116.74
Extreme 116.7438
127.4
1 month 116.74
Extreme 116.7438
130.83
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/26 Sell

Director

-25,000 0.0114%
8/17/26 Sell

Director

-5,000 0.0023%
8/10/26 Exercice

Chief Operating Officer

719,550 0.3320%
Change 5-day change 1-year change 3-year change Capi.($)
-2.16%-3.16%-18.35%+360.47% 26.38B
+0.06%+7.20%+54.04%+111.13% 74.27B
-2.29%-1.51%+33.30%+75.15% 61.21B
+0.28%+7.27%+31.74%+23.80% 27.55B
-1.95%+3.23%+0.67%-4.06% 25.34B
+0.57%+3.66%+25.59%-9.08% 20.84B
-1.47%+4.46%-8.09%+513.33% 14.94B
+1.29%-2.49%+163.31%+333.06% 15.17B
-2.83%-0.33%+42.15%+159.23% 14.41B
-4.35%-5.29%-14.44%+753.39% 13.66B
Average -1.29%+2.72%+30.99%+231.64% 29.38B
Weighted average by Cap. -1.11%+2.86%+33.22%+163.51%

Financials

2026 *2027 *
Net sales 1.81B 1.59B 1.49B 1.36B 2.55B 173B 2.57B 17.9B 6.94B 88.23B 6.78B 6.64B 286B 2.87B 2.52B 2.37B 2.16B 4.05B 275B 4.08B 28.44B 11.03B 140B 10.78B 10.54B 454B
Net income -350M -308M -289M -264M -494M -33.57B -498M -3.47B -1.35B -17.12B -1.32B -1.29B -55.5B 187M 164M 154M 141M 263M 17.87B 265M 1.85B 717M 9.11B 700M 685M 29.53B
Net Debt -632M -555M -521M -477M -891M -60.52B -897M -6.26B -2.43B -30.86B -2.37B -2.32B -100B -1.16B -1.02B -954M -872M -1.63B -111B -1.64B -11.46B -4.44B -56.49B -4.34B -4.25B -183B
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
26-09-23 US$118.28 -2.11% 1,066,276
26-09-22 US$120.82 -0.15% 2,405,270
26-09-21 US$121.00 +0.83% 1,812,278
26-09-18 US$120.00 -3.21% 3,445,007
26-09-17 US$123.98 +1.14% 1,592,254
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
120.82USD
Average target price
199.55USD
Spread / Average Target
+65.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!